Halozyme Launches TLANDO Oral Treatment for Testosterone Replacement

 -Halozyme Therapeutics, Inc.,  (NASDAQ: HALO) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO™ was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.

https://www.biospace.com/article/releases/halozyme-announces-commercial-launch-of-tlando-an-oral-treatment-for-testosterone-replacement-therapy/